SABI Mind and Filament Health Corp. Announce Psilocybin Supply Agreement
Filament’s naturally-derived psychedelic drug candidates to be made available for authorized SABI Mind clients
CALGARY, ALBERTA [June 10, 2022]: SABI Mind is pleased to announce a new licensing agreement with Filament Health Corp., a clinical-stage natural psychedelic drug development company. This agreement will allow patients qualifying under Health Canada regulations to access psilocybin-assisted therapies at all SABI Mind Healing Centres.
“There is a growing amount of evidence that psilocybin-assisted therapies are safe and effective treatments for end-of-life anxiety, intractable mental health conditions, and substance use disorders”, says Philippe Lucas PhD, psychedelic researcher and President of SABI Mind. “We look forward to working with the incredible team at Filament to provide legal access to these treatments via Health Canada’s Special Access Program (SAP) and clinical studies”.
Through this agreement, Filament Health will provide its unique botanical psilocybin drug candidates to SABI Mind’s clinical team for use by qualifying patients.
“We are thrilled to partner with SABI to enable their important psychedelic-assisted treatments and research,” said Benjamin Lightburn, Chief Executive Officer of Filament Health. “As one of a limited number of Health Canada-approved psilocybin suppliers, we hope to support patients who might benefit from psilocybin-assisted therapies whenever possible.”
This collaboration between Filament Health and SABI Mind provides increased access to psychedelic-assisted therapies to SABI clinics and qualified clinical staff, as well as Filament Health’s expanding suite of clinical trial support services.
About SABI Mind
Located in Calgary, SABI Mind supports the careful and necessary mending of mental health and chronic pain through psychedelic-assisted therapies. Founded by a group of Calgary-based entrepreneurs brought face-to-face with the challenges of those suffering from mental health conditions, SABI Mind empowers those discouraged by the conventional medical methods with a patient-centred treatment model supported by experienced psychiatrists, anesthesiologists, therapists, client experience specialists, and other clinic staff specially trained in ketamine-assisted psychotherapy. www.sabimind.com.
About Filament Health (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
Media Contact:
Lana Rogers
Gentle Lion Communications
403.519.7959